Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract by Finall, A I et al.
Subcutaneous inflammation mimicking metastatic malignancy
induced by injection of mistletoe extract
Finall, A. I., McIntosh, S. A., & Thompson, W. D. (2006). Subcutaneous inflammation mimicking metastatic
malignancy induced by injection of mistletoe extract. British medical journal, 333(7582), 1293-1294. DOI:
10.1136/bmj.39044.460023.BE
Published in:
British medical journal
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Published under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence that allows reuse subject only to the use being
non-commercial and to the article being fully attributed (http://creativecommons.org/licenses/by-nc/4.0).
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:16. Feb. 2017
Thanks to all participants in our study who provided a breath of
fresh air and a touch of humour. Thanks also to the members of
the evaluating committee for taking the risk and having some
fun together. Finally, thanks to Sarah Lafuente and Beatriz
Serrano for help in the statistical analysis.
Contributors: All authors designed the study. MA and MJB
designed the good looking score. AT and AML are guarantors.
Funding: None
Competing interests: AT is a physician and AML is a surgeon.
AT and MA have been happily married for 25 years. MA’s good
looking score for AT was not requested to avoid any problems at
home for Christmas.
Ethical approval: Submitted to the institutional review board
(IRB) but transferred for approval by the institutional beauty
review (IBR), an ad hoc subcommittee of our institution.
1 Rowland PA, Coe NPW, Burchard KW, Pricolo VE. Factors affecting the
professional image of physicians. Curr Surg 2005;62:214-6.
2 Isaacs D, Fitzgerald D. Seven alternatives to evidence based medicine.BMJ
1999;319:1618.
3 Gordon PM, Keohane SG, Herd RM. White coat effects. BMJ
1995;311:1704.
4 Wikipedia. Snow White. http://en.wikipedia.org/wiki/Snow_White.
(Accepted 20 October 2006)
doi 10.1136/bmj.39015.672373.80
Subcutaneous inflammation mimicking metastatic
malignancy induced by injection of mistletoe extract
A I Finall, S A McIntosh, W D Thompson
We describe the histological features of subcutaneous
inflammation induced by mistletoe, a popular Christ-
mas decoration, when used as an anticancer comple-
mentary therapy. We also outline the use of extract of
mistletoe in this context.
Case report
A 61 year old woman attending a follow-up
appointment two months after excision of tubular
carcinoma of the breast complained of an abdominal
wall mass. The lesion was subcutaneous, mildly tender,
and had a nodular consistency. The patient was
worried that the soft tissue mass might be a recurrence
of follicular lymphoma, which had been diagnosed in
April 2001, although her disease had been stable after
five cycles of chemotherapy. The possibility of
metastatic breast carcinoma was low considering the
good prognostic features of tubular carcinoma.
The lesion was excised and the 4×2×2 cm mass of
subcutaneous tissue seemed to consist solely of
fibroadipose tissue. Microscopically, we identified a
widespread infiltrate of plasma cells, lymphocytes, and
eosinophils within the subcutaneous adipose tissue, in
a septal and lobular distribution, indicating inflamma-
tion or panniculitisig.
A large proportion of the inflammatory cells were
eosinophils. The lymphocytes formed follicular aggre-
gates, particularly adjacent to blood vessels (fig 1). The
architecture of these aggregates was benign. The
lymphocytes were normal and immunohistochemistry
confirmed a normal distribution of T cells and B cells.
We found no evidence of light chain restriction, and
Bcl-2 immunoreactivity was negative within the follicle
centres, confirming the morphological impression of a
reactive lymphoid infiltrate with no evidence of follicu-
lar lymphoma.
In addition to the perivascular lymphoid aggre-
gates and panniculitis, lymphocytes and eosinophils
were seen within small blood vessel walls, indicating
vasculitis (fig 2). In summary, we found no evidence of
malignancy after the tissue was examined microscopi-
cally on multiple levels.
Lobular panniculitis with paraseptal lymphoid fol-
licles and vasculitis are found in lupus panniculitis,
which is seen in systemic and discoid lupus erythema-
tosus.1 Eosinophils have been reported in up to a quar-
ter of patients with this disorder, making it a possible
diagnosis in our patient.2 The microscopic features of
the subcutaneous inflammation seen in dermatomy-
ositis are indistinguishable from those seen in lupus,
but a muscle biopsy would be needed to make such a
diagnosis.3 Traumatic and factitial panniculitis are
characterised by a mixed lobular and septal pannicu-
litis, but they can be excluded in this case because of
the absence of fat cyst formation, necrosis, and
infiltrates of macrophages and multinucleate giant
cells.4 Such features are also seen in post-steroid
panniculitis, where multiple subcutaneous nodules
develop up to a month after cessation of steroids.5
Our patient satisfied none of the 11 diagnostic cri-
teria for systemic lupus erythematosus as set out by the
American Rheumatism Association.6 After discussion
with her surgeon, it transpired that the patient had
been receiving subcutaneous injections of mistletoe
extract as complementary therapy aimed at treating
her lymphoma. She used an aqueous, whole plant
extract of mistletoe grown on ash trees, called “Abnoba
Fig 1 Medium power view (×200) of follicular aggregates of
lymphoid cells in a perivascular distribution with a heavy infiltrate of
eosinophils in the background
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viscum fraxini.” This was a self administered subcutane-
ous injection (20 mg three times a week), which she
started 12 months before presentation. She had heard
about the use of mistletoe extract in palliative oncology
from a friend, and she was referred to a complemen-
tary therapist through her general practitioner. She is
still in remission two and a half years later with no fur-
ther side effects. Her injection site corresponded with
the site of excision so, in view of her negative investiga-
tions, signs, and symptoms of lupus erythematosus, we
considered the microscopic features to be a direct
inflammatory response to mistletoe extract and
conducted a review of the literature to compare our
findings.
Discussion
Mistletoe (Viscum album) is a semiparasitic woody per-
ennial that grows on several species of tree, including
elm, apple, pine, and oak.7 8 It is used as a Christmas
decoration in the United Kingdomwith the tradition of
kissing any person who lingers under it.
Mistletoe has been used to treat hypertension,
headaches, menstrual symptoms, and arthritis.8 The
first reference to its medical use is in the Bible as a
cure for epilepsy. The young King David is said to have
seen a woman collapse in a fit. An angel appeared to
him as he prayed for a remedy, announcing “Whoever
wears the oak mistletoe in a finger ring on the right
hand, so that the mistletoe touches the hand, will
never again be bothered by the falling sickness.”9
Today, despite the lack of robust data supporting the
use of mistletoe as an anticancer drug, it is widely used
in middle Europe; around €23m (£16m; $30m) is
spent on the preparation each year,9 and up to two
thirds of oncology patients use it.10 Sixteen ran-
domised controlled trials have been published to date,
many of which lack formal statistical power calcula-
tions and enlist small numbers of patients.7 10 11 Several
of these studies analysed quality of life variables as
their major outcomes and failed to blind patients to
their treatment, thereby severely biasing their
results.10 11 The evidence of benefit from human stud-
ies is weak, but animal studies and in vitro laboratory
evidence suggest that mistletoe may be beneficial to
cancer patients.7 Rigorous randomised controlled
trials are needed to provide conclusive data in
humans.7 10 11
Local reactions have been documented previously,
usually manifesting as erythema or pain.12 Two reports
of histologically assessed inflammation induced by
mistletoe exist in the medical literature. A 61 year old
man with a T3NXMX pancreatic adenocarcinoma
who was treated with once weekly intratumorous and
peritumorous injections of mistletoe for five weeks
underwent diagnostic needle core biopsy on day 28
after starting treatment. The biopsy showed adeno-
carcinoma admixed with neutrophils and eosino-
phils.13 A further study documents the histology of
seven patients with subcutaneous inflammation
induced by whole plant mistletoe extract. The
microscopic pattern was of a dense perivascular
lymphoid infiltrate and increased monocytes.14 An
infiltrate of plasma cells or eosinophils was not seen.
Both accounts support the notion that the micro-
scopic features of panniculitis in our case are caused
by subcutaneous mistletoe administration. Ours is the
first documented account of a combined pattern of a
heavy infiltrate of eosinophils, perivascular lymphoid
aggregates, and mild vasculitis.
This case taught us the importance of good
communication. We may never have known the under-
lying cause of the inflammation without an honest
working relationship between the pathologists and
surgeons, and between the surgeon and his patient.
This story also shows that patients sometimes withhold
information from us. In this case, the patient may have
assumed that alternative therapies have no relevance in
conventional medical consultations.
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Fig 2 High power view (×400) showing vasculitis—small blood
vessel destruction and inflammation with a prominent eosinophilic
component. Note the red blood cells within the vessel lumens
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